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ABSTRACT
Background Tetralogy of Fallot (TOF) is common in
individuals with hemizygous deletions of chromosome
22q11.2 that remove the cardiac transcription factor TBX1.
Objective To assess the contribution of common and rare
TBX1 genetic variants to TOF.
Design Rare TBX1 variants were sought by resequencing
coding exons and splice-site boundaries. Common TBX1
variants were investigated by genotyping 20 haplotype-
tagging SNPs capturing all the common variations present
at the locus. Association analysis was performed using the
program UNPHASED.
Patients TBX1 exons were sequenced in 93 patients with
non-syndromic TOF. Single nucleotide polymorphism
analysis was performed in 356 patients with TOF, their
parents and healthy controls.
Results Three novel variants not present in 1000
chromosomes from healthy ethnically matched controls
were identified. One of these variants, an in-frame 57
base-pair deletion in the third exon which removed 19
evolutionarily conserved residues, decreased
transcriptional activity by 40% in a dual luciferase assay
(p¼0.008). Protein expression studies demonstrated that
this mutation affected TBX1 protein stability. After
correction for multiple comparisons, no significant
associations between common genetic variants and TOF
susceptibility were found.
Conclusion This study demonstrates that rare TBX1
variants with functional consequences are present in
a small proportion of non-syndromic TOF.
INTRODUCTION
Congenital heart defects (CHD) occur in approxi-
mately seven out of every 1000 live births.1
Tetralogy of Fallot (TOF), which accounts for
approximately 7% of CHD and is the commonest
cyanotic CHD,2 occurs in a number of syndromes
but in the majority of cases is an isolated defect.
Chromosome 22q11.2 deletions account for
approximately 7% of TOF cases3 4 and trisomy 21
accounts for a further 5% of cases.3 A rarer
syndromic association is Alagille syndrome which
results from JAG1 haploinsufficiency or intragenic
mutation. The advent of array-based molecular
karyotyping has shown that approximately
another 10% of cases are the result of copy number
variants.5 However, around 75% of cases are unex-
plained and are thought to result from a complex
interaction of environmental and genetic factors. In
support of this model, substantial genetic influ-
ences have been inferred for certain malformations
in studies of familial recurrence risk ascertained
through non-syndromic patients.6 A CHD risk of
3.1% in offspring and 2.2% in siblings of patients
with TOF has been reported, indicating a substan-
tial increase in CHD risk for first-degree relatives of
cases compared with the general population.6
CHD is common in patients with chromosome
22q11.2 deletion, with 17% of patients with
22q11.2 deletions having TOF.7 The deletion, which
is mediated by non-homologous recombination
between low copy repeats, typically removes
a genomic segment including the cardiac tran-
scription factor TBX1. TBX1-expressing progenitors
contribute to the majority of the outflow tract
(OFT) and right ventricle of the developing
heart.8e13 Studies in mouse models have shown
that Tbx1 deletions or null mutations in the mouse
cause CHD including OFT lesions.8 10 14 15 Human
studies have identified nine novel variants of TBX1
that alter protein sequence in patients who have
clinical features of the 22q11.2 deletion syndrome,
including CHD, but who do not carry a chromo-
somal microdeletion.16e19 Some of these mutations
completely ablate TBX1 function in vitro, while
others result in a gain of TBX1 function, suggesting
an optimal range of TBX1 activity above or below
which the risk of malformations increases.
We hypothesised that hypomorphic alleles of
TBX1 which reduce but do not completely ablate
TBX1 function, might be involved in susceptibility
to non-syndromic TOF. Variants affecting TBX1
expression levels and thus potentially predisposing
to TOF risk, could be rare or common; no previous
study has investigated the role of common single
nucleotide polymorphisms (SNPs) in the TBX1 gene
in TOF susceptibility. In this study, we screened
patients with non-syndromic TOF for rare genetic
variants in all coding exons of TBX1 by rese-
quencing and performed association analysis of
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common haplotype-tagging SNPs (htSNPs) in and around TBX1
in trio families, cases and controls.
MATERIAL AND METHODS
Study population
Patients with TOF, of White European ancestry, were recruited
from four UK paediatric cardiology centres. Clinical records were
reviewed before recruitment, and probands with known chro-
mosomal abnormalities, other recognised syndromes, learning
difficulties, or known maternal exposure to significant terato-
gens during pregnancy were excluded. Parental samples were
obtained where possible. Proband samples were screened for
22q11.2 deletion by multiplex ligation-dependent probe ampli-
fication (MRC-Holland, Amsterdam, Netherlands), and samples
with deletions were excluded from further analysis. Ethical
approval was given for the study and fully informed consent
was obtained from all participants (or their parents, if children
were too young to themselves consent). DNA was extracted
from blood or saliva samples using standard protocols.
Exon sequencing
TBX1 coding sequence and consensus splice sites were sequenced
in 93 unrelated TOF probands. Intronic PCR primers were
designed based on transcripts NM_080646, NM_005992 and
NM_080647 (www.ncbi.nlm.nih.gov, accessed 26 July 2010). PCR
products were cleaned before bi-directional dideoxy sequencing
and sequence traces analysed using the Staden Package suite of
programs (http://staden.sourceforge.net/, accessed 26 July 2010).
Previously unreported variants found in the TOF probands were
genotyped in 1000 control chromosomes.
Constructs and luciferase assays
The TBX1 variants c.115G/A and c.129_185del57 were intro-
duced into the TBX1 expression construct TBX1-pcDNA318 by
site-directed mutagenesis. TBX1 constructs were transfected into
U2-OS cells along with pGL2tk-2xT, which contains two copies
of the T-binding site adjacent to firefly luciferase,19 and Renilla
luciferase control. RNA was extracted from transfected cells
using standard techniques, DNAase treated to avoid amplifica-
tion of remaining transfected plasmid and Taqman relative-
quantification real-time PCR (Applied Biosystems, California,
USA) performed to check that equivalent levels of transcript
were obtained for TBX1 and the TBX1 variants. The transcrip-
tional activity of TBX1 and the TBX1 variants was then
measured by comparison of the firefly luciferase reading with the
Renilla luciferase control (dual luciferase assay).
Immunocytochemistry
HEK293 cells were seeded on glass cover slips and transfected
with wild-type or variant TBX1. Twenty-four hours after
transfection, cells were fixed, permeabilised with 0.1% Triton X-
100 in phosphate-buffered saline (PBS) and after blocking with
5% goat serum in PBST probed with rabbit anti-Tbx1 antibody
(Zymed) followed by the secondary antibody (Cy3 conjugated
sheep anti-rabbit antibody, Sigma). Cells were mounted with
VectaShield containing 4,6-diamino-2-phenylindole.
Protein expression and stability
The stability of the p.Pro43_Pro61del variant protein was
compared with the wild-type protein using cycloheximide inhi-
bition of de novo protein synthesis followed by western blot
analysis. HEK293 cells were transfected with wild-type or variant
TBX1. Twenty-four hours after transfection, cells were treated
with 25 mg/ml cycloheximide and lysed at 2 h intervals using 2X
sodiumdodecyl sulphate denaturing buffer (0.5 MTris pH 6.8, 4%
sodium dodecyl sulphate (w/v), 20% glycerol, 1.5% dithiothreitol
(w/v)). Proteins were resolved on a 12% polyacrylamide gel and
transferred onto Hybond ECL membrane (GE, Buckinghamshire,
UK). Membranes were probed with anti-Tbx1 antibody (Zymed)
and anti-nucleolin antibody (Bethyl, Montgomery, TX, USA) as
a loading control then detected with horseradish peroxidase-
conjugated anti-rabbit antibody (Jackson ImmunoResearch,West
Grove, PA, USA) using West Dura ECL kit (Thermoscientific,
Rockford, IL, USA). Band intensities were measured in Adobe
Photoshop, normalising TBX1 expression to the loading control.
SNP genotyping
Three hundred and fifty-six patients with TOF, comprising 203
parentechild trios, 80 parentechild duos, 67 singleton probands
and six probands from three multiplex families were genotyped.
One hundred and eighty-two unrelated healthy individuals, free
of CHD, of White European ancestry were also genotyped as
controls for those cases where family members were not avail-
able. Sixteen htSNPs were selected from 15 kb upstream of TBX1
to 4.5 kb downstream of TBX1 using the HapMap data for the
samples of Northern and Western European ancestry (CEU
samples; http://www.hapmap.org, accessed 27 July 2010) and
the Tagger utility of Haploview v3.2 (http://www.broad.mit.
edu/mpg/haploview, accessed 27 July 2010). These htSNPs had
a minor allele frequency>0.05 and were in linkage disequilibrium
at r2>0.8 with all other genetic variations within the region. Four
additional SNPs (rs5748418, rs737868, rs13054377 and
c.1189A/C), which were identified by sequencing of the TOF
cases andwhichwere not in linkage disequilibrium (R2<0.8) with
the selected ht SNPs, were also included.
Statistical analysis
Luciferase activation by control and mutant TBX1 proteins and
mRNA production from the different TBX1 constructs in cell
culture, were compared using paired t tests. TBX1 wild-type and
the p.Pro43_Pro61del variant protein concentration after cyclo-
heximide treatment was analysed using analysis of variance
(assuming a general linear model) and regression analysis in
Minitab 15. Genotype data were checked for Mendelian
consistency within the families and for HardyeWeinberg equi-
librium using PEDSTATS.20 Association analysis of the SNP
genotypes within the families and unrelated controls was
performed using UNPHASED version 3.0.9.21 UNPHASED was
chosen in view of the program’s capacity to handle datasets
including both trio families and unrelated cases and controls and
carry out genotype and haplotype association tests yielding p
values for the entire dataset.
RESULTS
Sequencing TBX1 in probands
Sequencing 93 TOF probands identified four previously unre-
ported genetic variants present in eight probands. Three novel
variants (c.115G/A, c.129_185del57 and c.1074G/A), were
each present in one proband and absent from 1000 control
chromosomes. The single-base substitution c.115G/A,
resulting in a p.Gly39Ser amino acid substitution in exon 3 of
TBX1, was inherited from a phenotypically normal mother. The
patient with the 57 bp deletion (c.129_185del57) resulting in the
in-frame amino acid deletion p.Pro43_Pro61del was noted to
have a right-sided aortic arch. He inherited the change from his
mother who has no history of congenital heart disease. A
synonymous base substitution c.1074G/A was present in the
exon 9C major isoform (NM_080647 isoform C) of a third
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proband and was also inherited from a phenotypically normal
mother. The fourth previously unreported variant was a synon-
ymous base substitution c.75G/T, p.Gly25Gly, present in five
probands and seen in 20 of 1000 control chromosomes. These
synonymous variants were thought unlikely to be causative and
were not investigated further.
The glycine of the assumed amino acid substitution
p.Gly39Ser is conserved in chimpanzee, rat, mouse and opossum
(Monodelphis domestica) but is substituted by serine in the frog
(Xenopus tropicalis and Xenopus laevis) and fish (Tetraodon nigro-
virdis and Danio rerio). The sequence of the assumed 19 amino
acid deletion p.Pro43_Pro61del shows a high degree of conser-
vation in rat, mouse and opossum. The p.Pro52, p.Cys53 and
p.Ala55 residues were also completely conserved in platypus
(Ornithorhynchus anatinus), frog and fish.
Functional investigation of novel TBX1 variants
The mRNA expression of the wild-type construct and the two
constructs incorporating mutations that changed the amino acid
sequence (c.115G/A and c.129_185del57) was shown to be
equal by relative quantification real-time PCR (p>0.05; data not
shown). In the dual luciferase assay, the p.Gly39Ser TBX1
protein showed no significant difference in transcriptional
activity from wild-type TBX1 (p¼0.23; figure 1). The
p.Pro43_Pro61del TBX1 protein, however, showed a significant
40% reduction in transcriptional activity compared with wild-
type TBX1 (p¼0.008; figure 1). Immunocytochemistry demon-
strated that both the p.Gly39Ser mutated protein (not shown)
and the 19 amino acid deleted protein locate to the nucleus,
indicating that these mutations do not perturb protein local-
isation (figure 2). We next assessed the stability of the protein
expressed from the c.129_185del57 TBX1 construct. There was
no significant difference in the basal level of TBX1 protein
expressed in cells transfected with the wild-type TBX1 or
mutated TBX1 construct in three independent experiments
(p¼0.549). There was a significant difference in the rate at
which intracellular TBX1 levels decreased after treatment with
cycloheximide with the mutant protein being less stable in three
independent experiments (p¼0.003; figure 3).
Association analysis of htSNPs
The founder genotypes for all 20 TBX1 htSNPs were shown to be
in HardyeWeinberg equilibrium (p>0.01). Genotype and
haplotype frequencies were in good agreement with HapMap
data, for those markers where it was available. The likelihood
ratio statistics and associated p values from the UNPHASED
genotype analysis of the 20 TBX1 htSNPs in the TOF families
and controls are shown in table 1. Three SNPs (rs739374,
rs6518580 and rs5993820) showed borderline significant associ-
ation (p¼0.016e0.025) with TOF in 356 cases. However, this
seems unlikely to reflect true association as these results do not
withstand correction for multiple testing.
DISCUSSION
We have carried out a comprehensive analysis of both common
and rare TBX1 genetic variation in patients with non-syndromic
TOF. Sequencing TBX1 exonic and splice site regions identified
four previously unreported coding variants; three of which
(c.115G/A, c.129_185del57 and c.1074G/A) were not present
in 1000 control chromosomes. The c.129_185del57 variant,
which deletes 19 evolutionarily conserved amino acids, was
found to reduce the transcriptional activity of TBX1 by 40%.
The decreased transcriptional activation observed supports our
a priori hypothesis that if among the developmental processes
perturbed by 22q11.2 deletion, normal cardiovascular develop-
ment is particularly susceptible to differences in TBX1 activity,
then hypomorphic alleles may confer risk of non-syndromic
CHD. As the p.Pro43_Pro61 deletion is outside the DNA binding
domain, which extends from aa119 to aa297, we next assessed
whether subcellular localisation or protein stability were
affected by the mutation. We found that the mutant protein
localised appropriately to the nucleus but that it was less stable
than wild-type protein. Thus a mechanism by which it leads to
decreased transcriptional activity is that TBX1 protein levels are
diminished, though this may not be the sole mechanismdfor
example, the deletion may also affect dimerisation or interaction
with other partners. It is interesting that in addition to TOF this
child also had a right-sided aortic arch, an abnormality reported
in Tbx1 mutant mice.13 The c.115G/A, p.Gly39Ser variant did
not affect transcriptional activity in the in vitro assay; however,
this assay does not fully recapitulate the complex interactions
occurring in the developing embryo. Transcription factors act on
target genes in concert and as more becomes known about TBX1
protein interactions the effect of this mutation on protein
interactions should be investigated. As yet, little is known about
Tbx1 protein interactions but Tbx1 has recently been shown to
interact with Srf (serum response factor), a regulator of muscle
differentiation,22 and with SMAD1, affecting BMP signalling in
a transcription independent manner.23
Although TBX1 mutations had been identified in studies of
patients who have clinical features of chromosome 22q11.2
deletion syndrome, including CHD, but who are not deleted for
the region,16e19 early studies of TBX1 in non-syndromic TOF
were small and failed to identify mutations. A substantially
larger recent study of 191 patients with TOF who did not have
a chromosomal abnormality or recognised syndrome identified
two novel TBX1 variants.3 One of these p.Pro290Ser, not present
in 174 control individuals and inherited from a phenotypically
normal father, did not affect transcriptional activity in vitro.
The second, a 30 bp insertion, leading to expansion of a poly-
alanine tract, decreased transcriptional activity in vitro; further
studies showed aggregation of the expressed mutant protein in
the cytoplasm. Taking the two studies together it is evident that
TBX1 coding sequence mutations do occur in patients with non-
syndromic TOF but account for only about 1% of cases.
A recent study has demonstrated a non-linear relationship
between Tbx1mRNA dosage and the 22q11.2 deletion syndrome
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Figure 1 Transcriptional activation of a luciferase reporter by wild-type
(WT) and mutant TBX1. Wild type TBX1-pcDNA3 construct activates
transcription, as does the G39S missense construct (c.115G/A),
whereas the c.129_185del57 construct, resulting in an in-frame 19
amino acid deletion (p.Pro43_Pro61del) shows a significantly reduced
transcriptional activity compared with the wild-type (40%, p¼0.008).
Results were normalised to Renilla luciferase for transfection efficiency
and to pcDNA3 and are expressed as average values 6 SD of three
replicates. Results were confirmed in another three independent assays,
all showing significant p values (0.002e0.02).
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phenotype, including cardiac OFT defects, in the mouse.24 The
penetrance of cardiac OFT defects was shown to sharply
increase at mRNA concentrations of less than about 20% of
normal in that study; the equivalent threshold for TBX1 activity
in man is unknown, although our study suggests that human
OFT development is sensitive to smaller decreases in TBX1
activity. In vitro studies of three TBX1 missense changes iden-
tified in patients with the 22q11.2 phenotype found increased
transcriptional activity.19 Similarly, investigation of a 59
untranslated change, -39C/T, identified in patients with the
22q11.2 phenotype showed this to be associated with increased
transcript levels.16 25 Thus human OFT development appears to
Figure 2 Subcellular localisation of
TBX1 wild-type and mutant protein in
transiently transfected HEK293 cells
stained with 4,6-diamino-2-phenylindole
(DAPI) and analysed by
immunocytochemistry with anti-Tbx1
antibody.
Figure 3 (A) Representative western
blot showing TBX1 protein expression
after 0e6 h cycloheximide treatment in
HEK293 cells transfected with either the
wild-type (WT) TBX1-pcDNA3
construct or the c.129_185del57 TBX1-
pcDNA3 construct. The 19 amino acid
deletion in the p.Pro43_Pro61del TBX1
protein results in the smaller protein size
detected in these samples. Both bands
were TBX1-specific (checked using an
empty pcDNA3 transfected control,
data not shown). The upper TBX1 band
for both wild-type and
p.Pro43_Pro61del samples is believed
to result from phosphorylation or other
post-translational modification of TBX1
as the lower band is of the expected
size for wild-type TBX1 isoform C
(w56 kDa). (B) Scatter plot showing
TBX1 protein expression normalised to
nucleolin (loading control) for three
independent experiments 0e6 h after
cycloheximide treatment of cells
transfected with the wild-type TBX1
construct (full squares) compared with
cells transfected with the
c.129_185del57 TBX1 construct (open
circles). Regression analysis of the
three replicates describes the slopes of
the lines; 4.6% (wild-type TBX1) and
17.8% (p.Pro43_Pro61del TBX1), as
significantly different (p¼0.003).
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be sensitive to decreased activity and also to increased TBX1
activity.
Systematic study of all common variation in the TBX1 region in
356 TOF cases, together with available parents and unrelated
controls, provided no support for the hypothesis that common
SNPs in this region have sizeable effects (ie, conferring ORs>2.0)
on the risk of TOF, although the possibility smaller effects of
common variants cannot be ruled out. No previous studies have
investigated the potential contribution of common TBX1 genetic
variants in TOF. For common conditions such as coronary disease,
the contribution of SNPs to risk, discovered by genome-wide
association studies, has been small, with ORs generally <1.3.
However, some rarer diseases have been shown to be influenced to
a greater extent by commonvariants. For example, Crohn’s disease
has a population prevalence approximately equal to that of
congenital heart disease. SNPs in the Nod2/CARD15 gene with
minor allele frequencyw0.05 are associated with Crohn’s disease
risks of 2.2e4.0 to heterozygotes and around 17.0 to homozy-
gotes26; this study had>80%power at p<10-5 to detectCHD risks
of this magnitude associated with SNPs of similar frequency.
Previous studies suggesting an oligogenic aetiology for TOF
increased the a priori likelihood that effects of this size might be
present.6We had lowpower to detect common variants associated
with relative risks <2.0 and larger studies will be required to
conclusively establish the presence or absence of such smaller
effects at TBX1. More generally, genome-wide association studies
in largenumbers of patients and family-based or unrelated controls
will be required to resolve whether common genetic variation
importantly influences non-syndromic CHD susceptibility.
In summary, this study is the first comprehensive investiga-
tion of common and rare TBX1 genetic variants in non-
syndromic TOF cases. It has identified a rare novel functional
genetic variant that is a likely susceptibility factor to TOF.
However, as the study indicates that mutations in TBX1 account
for at most a few per cent of the susceptibility to non-syndromic
TOF it does not support the introduction of TBX1 mutation
analysis to clinical practice in this patient group; systematic
large-scale surveys of other CHD candidate genes will be
necessary to identify the genetic risk factors accounting for the
bulk of the heritability seen in epidemiological studies.
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Table 1 Association analysis of TBX1 genotypes
SNP
TOF (356)
LR p Value
rs885988 5.195 0.074
rs7293017 1.077 0.584
rs739374 8.284 0.016*
rs8135854 4.011 0.135
rs6518580 7.352 0.025*
rs16984141 1.845 0.397
rs7291533 0.914 0.633
rs5993820 8.079 0.018*
rs1005133 1.672 0.434
rs4819520 1.726 0.422
rs5748418 1.719 0.423
rs737868 0.718 0.698
rs2301558 0.530 0.767
rs13054377 3.683 0.159
1189CA 1.553 0.460
rs2238777 0.892 0.640
rs4819522 0.121 0.941
rs5746826 2.851 0.240
rs5748425 0.097 0.953
rs5748427 0.173 0.917
Likelihood ratio (LR) c2 statistics with nominal uncorrected associated
probabilities (p value) for ‘UNPHASED’ analysis of TBX1 genotypes in the
356 TOF families.
*p Values <0.05.
SNP, single nucleotide polymorphism; TOF, tetralogy of Fallot.
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